NICE Vitamin D

8/10/2019 NICE Vitamin D

1/53

Vitamin D: increasing supplementuse among at-risk groups

!I: &J 2014

NICE public health guidance 56I...I/


2/53

Contents


3/53

@ H .......................................................................................................................................... 19

# H JH D I@H ................................................................................... 20

K H H JH D I@H.......................................................................................................... 21

4 CH .......................................................................................................................... 22

BI ............................................................................................................................................ 22

CIH...................................................................................................................................... 23

AJ@@HM JH D I@H...................................................................................................... 23

EJ.................................................................................................................................................. 24

@H


4/53

8 * ................................................................................................................................ 37

9 IM H


5/53

What is this guideline about?

Introduction


6/53

Clinical judgement

C@@ >IH K@@ H H K


7/53

1 Recommendations


8/53

EI IHI I@HJH I@H H @I H


9/53

$H @ K K


10/53

EH@


11/53

H I H@ H , H HIH @H


12/53

@@ HH


13/53


14/53

K KH< @@ HH, @ @ H H@ H@

@@ IH H I H IH JH D I@HI@@M H.


15/53

2 Who should take action?

Introduction


16/53

Who should take action in detail

Recommendation 1

DHH @H


17/53

Recommendation 9

I@ @H< E@; @H< EIH E@; @@ I;


18/53

3 Context

Background

H D H@ @H@ KH<


19/53

H


20/53

&H@ DH &IHH IJM IH H


21/53

@ H H H


22/53

4 Considerations


23/53

Communications

4.3 AJ H


24/53

H


25/53

H@ @@ @J@. K @ K H


26/53

4.13


27/53

BI H


28/53

4.20 A @HH H


29/53

5 Recommendations for research


30/53

5.3 K I@HM < H J K, J@@HM

IH JH D I@H H H@


31/53

6 Related NICE guidance

Published

F@@: H JH @@ @ @ &!CE I@ CG161 (2013).

B


32/53

7 Glossary

At-risk groups

I@H I H


33/53

IHM I H J K , H, HJH.

F L@, H


34/53

J


35/53

Low vitamin D status

$K JH D HHI (H @@ JH D M) M H


36/53

Vegan

@ K


37/53

8 References

" , C A, H @. (2013)A I@HHJ HIM IH JH

E@. A


38/53

9 Summary of the methods used to develop this guideline

Introduction


39/53

1. K HJ H HJ HJH H K @HH

LH I JH D


40/53

< H K

@@ J I M &!CE < 2013.

Selection criteria

HI K @I H


41/53

Quality appraisal

!@I K H


42/53

Economic modelling

A @ K HIH, H H H


43/53

E @HH M HH


44/53

10 The evidence

Introduction


45/53

Recommendation 7: J HHH 1.7; E; !DE

Recommendation 8: J HHH 1.10, 1.11, 2.2, 2.9

Recommendation 9: J HHH 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.10, 1.11, 2.3, 2.4, 2.5,

2.13

Recommendation 10: J HHH 1.10, 1.11, 1.12, 2.14

Recommendation 11: J HHH 2.6; !DE

Economic modelling


46/53

11 Gaps in the evidence


47/53

12 Membership of the Public Health Advisory Committee

and the NICE project team

Public Health Advisory Committee A

&!CE


48/53

Lucy Yardley

@H< M


49/53

Caroline Mulvihill

A@MH

Alastair Fischer

H (I H "I 2014)

Rupert Franklin

>H ( "I 2014)

Rukshana Begum

CH

Sue Jelley

EH

Susie Burlace

EH

H D: I@H I H- I &!CE I@


50/53

About this guideline

What does this guideline cover?


51/53

F H


52/53

H H


53/53

&!CE

NICE Vitamin D

Documents

Transcript of NICE Vitamin D